On Friday, Evolus reached a key technical benchmark, with its Relative Strength (RS) Rating entering into the 80-plus percentile with an improvement to 82, a rise from 75 the day before.
This proprietary rating measures market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the trailing 52 weeks matches up against that of all other stocks.
Over 100 years of market history reveals that the best stocks often have an RS Rating north of 80 in the early stages of their moves.
Hone Your Stock-Picking Skills By Focusing On These Factors
Evolus is working on a with a 17.82 entry. See if it can break out in volume at least 40% above average.
Evolus reported 0% earnings growth last quarter. Sales gains came in at 22%. Look for the next report on or around Feb. 26.
Evolus holds the No. 9 rank among its peers in the Medical-Ethical Drugs industry group. Phibro Animal Health, Jazz Pharmaceuticals and Novartis ADR are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Technical Action?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
